Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths

Luciana M.Martel Duguech, Richard Legro

Research output: Contribution to journalArticle

Abstract

Polycystic ovary syndrome (PCOS) is a complex disorder which interacts with other genetic and environmental factors to cause dysregulation of steroidogenesis and anovulation as well as insulin resistance. Treatments which address the long-term effects of this unique combination of reproductive and metabolic dysfunction are needed. Over the past decade, new insights into the genetic factors of PCOS and biotechnological advances have led to potential treatments for women with PCOS. These treatments include both new potent pharmaceutical compounds and repurposed drugs which target different steps in metabolic-reproductive pathways to improve long-term health of women with PCOS. These new therapies target key enzymes involved in steroidogenesis, regulatory pathways of gonadotropin secretion, or lower oxidative stress. We review in this article the current common treatments of PCOS, recent developments in the field, and current information on the mode of action, efficacy, and safety of emerging therapeutic compounds.

Original languageEnglish (US)
Pages (from-to)326-343
Number of pages18
JournalSeminars in Reproductive Medicine
Volume35
Issue number4
DOIs
StatePublished - Jul 1 2017

Fingerprint

Polycystic Ovary Syndrome
Therapeutics
Drug Repositioning
Anovulation
Secretory Pathway
Women's Health
Metabolic Networks and Pathways
Gonadotropins
Insulin Resistance
Oxidative Stress
Safety
Enzymes
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Obstetrics and Gynecology
  • Physiology (medical)

Cite this

@article{65ae909dbfc14255bc8be8030fc80a6a,
title = "Pharmacologic Treatment of Polycystic Ovary Syndrome: Alternate and Future Paths",
abstract = "Polycystic ovary syndrome (PCOS) is a complex disorder which interacts with other genetic and environmental factors to cause dysregulation of steroidogenesis and anovulation as well as insulin resistance. Treatments which address the long-term effects of this unique combination of reproductive and metabolic dysfunction are needed. Over the past decade, new insights into the genetic factors of PCOS and biotechnological advances have led to potential treatments for women with PCOS. These treatments include both new potent pharmaceutical compounds and repurposed drugs which target different steps in metabolic-reproductive pathways to improve long-term health of women with PCOS. These new therapies target key enzymes involved in steroidogenesis, regulatory pathways of gonadotropin secretion, or lower oxidative stress. We review in this article the current common treatments of PCOS, recent developments in the field, and current information on the mode of action, efficacy, and safety of emerging therapeutic compounds.",
author = "Duguech, {Luciana M.Martel} and Richard Legro",
year = "2017",
month = "7",
day = "1",
doi = "10.1055/s-0037-1603729",
language = "English (US)",
volume = "35",
pages = "326--343",
journal = "Seminars in Reproductive Medicine",
issn = "1526-8004",
publisher = "Thieme Medical Publishers",
number = "4",

}

Pharmacologic Treatment of Polycystic Ovary Syndrome : Alternate and Future Paths. / Duguech, Luciana M.Martel; Legro, Richard.

In: Seminars in Reproductive Medicine, Vol. 35, No. 4, 01.07.2017, p. 326-343.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacologic Treatment of Polycystic Ovary Syndrome

T2 - Alternate and Future Paths

AU - Duguech, Luciana M.Martel

AU - Legro, Richard

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Polycystic ovary syndrome (PCOS) is a complex disorder which interacts with other genetic and environmental factors to cause dysregulation of steroidogenesis and anovulation as well as insulin resistance. Treatments which address the long-term effects of this unique combination of reproductive and metabolic dysfunction are needed. Over the past decade, new insights into the genetic factors of PCOS and biotechnological advances have led to potential treatments for women with PCOS. These treatments include both new potent pharmaceutical compounds and repurposed drugs which target different steps in metabolic-reproductive pathways to improve long-term health of women with PCOS. These new therapies target key enzymes involved in steroidogenesis, regulatory pathways of gonadotropin secretion, or lower oxidative stress. We review in this article the current common treatments of PCOS, recent developments in the field, and current information on the mode of action, efficacy, and safety of emerging therapeutic compounds.

AB - Polycystic ovary syndrome (PCOS) is a complex disorder which interacts with other genetic and environmental factors to cause dysregulation of steroidogenesis and anovulation as well as insulin resistance. Treatments which address the long-term effects of this unique combination of reproductive and metabolic dysfunction are needed. Over the past decade, new insights into the genetic factors of PCOS and biotechnological advances have led to potential treatments for women with PCOS. These treatments include both new potent pharmaceutical compounds and repurposed drugs which target different steps in metabolic-reproductive pathways to improve long-term health of women with PCOS. These new therapies target key enzymes involved in steroidogenesis, regulatory pathways of gonadotropin secretion, or lower oxidative stress. We review in this article the current common treatments of PCOS, recent developments in the field, and current information on the mode of action, efficacy, and safety of emerging therapeutic compounds.

UR - http://www.scopus.com/inward/record.url?scp=85031707883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031707883&partnerID=8YFLogxK

U2 - 10.1055/s-0037-1603729

DO - 10.1055/s-0037-1603729

M3 - Article

C2 - 29036740

AN - SCOPUS:85031707883

VL - 35

SP - 326

EP - 343

JO - Seminars in Reproductive Medicine

JF - Seminars in Reproductive Medicine

SN - 1526-8004

IS - 4

ER -